XBiotech Inc. (XBIT)
| Market Cap | 556.10M |
| Revenue (ttm) | 38.73M |
| Net Income (ttm) | 677.11M |
| Shares Out | 29.04M |
| EPS (ttm) | 16.45 |
| PE Ratio | 1.16 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $19.11 |
| Previous Close | $18.94 |
| Change ($) | 0.17 |
| Change (%) | 0.90% |
| Day's Open | 19.17 |
| Day's Range | 18.58 - 19.52 |
| Day's Volume | 116,902 |
| 52-Week Range | 8.72 - 21.48 |
With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain With New Infectiou...
Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Member...
These are the small cap stocks with the best value, fastest growth, and most momentum for January 2021.
These are the small cap stocks with the best value, fastest growth, and most momentum for December 2020.
XBiotech Inc. is a clinical-stage biopharmaceutical company focused on developing safer/more effective therapeutics through human-based monoclonal antibodies. XBiotech's pipeline consists of 4...
Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential
These are the small cap stocks with the best value, fastest growth, and most momentum for November 2020.
As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBI...
These are the small cap stocks with the best value, fastest growth, and most momentum for October 2020.
With the Arrival of Flu Season, Development of a Breakthrough Therapeutic for Treating Influenza and COVID-19 Co-Infections is Urgently Needed With the Arrival of Flu Season, Development of a ...
These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.
These are the small cap stocks with the best value, fastest growth, and most momentum for September.
FDA has Authorized Use of Antibody-Rich COVID-19 Therapy Derived from Convalescent Patients
XBiotech Inc. (NASDAQ: XBIT) shares made a handy gain on Monday after the company said that it has identified True Human antibodies that could potentially be used as a therapy against SARS-CoV2.
The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immun...
Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.
XBiotech: Well Funded, Working On The Next Bermekimab, And Undervalued
After Sale of its Previous Anti-IL-1a True Human Antibody, Company Now Has Production Cell to Manufacture New Molecule for Launch of Clinical Studies in 2021 After Sale of its Previous Anti-IL...
When Wall Street ignores micro-cap stocks, it creates deep value opportunities, if a company is able to turn things around against fortune.
Antibody Therapy Targeting Interleukin-1a significantly reduced stroke related brain injury in animals and points to new potential blockbuster therapy Antibody Therapy Targeting Interleukin-1a...
These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.
Donors with Potent Natural Immunity Against the Virus are Identified as the Starting Point for XBiotech’s Drug Development Program to Treat COVID-19
These are the small cap stocks with the best value, fastest growth, and most momentum for May.
These exciting stocks to buy for aggressive investors might be small, but they have massive growth potential when the pandemic clears up. The post 7 Top Stocks to Buy for Aggressive Investor...
New antibody to block IL-1⍺ scheduled to enter clinical trials as next generation anti-inflammatory therapy in 2021 New antibody to block IL-1⍺ scheduled to enter clinical trials as next gener...
AUSTIN, Texas, April 03, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) and BioBridge Global today announced their collaboration to participate in a U.S. Food and Drug Administration ...
AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:...
AUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) -- This press release corrects a prior version published on February 13, 2020 and is updated to revise the preliminary proration factor. The co...
The company's offer to buy back shares was overtendered, resulting in a prorated deal.
AUSTIN, Texas, Feb. 13, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired...
XBiotech Is Trading Below Its $30 Offer Price For Good Reason, But It Still Could Rise
The company is offering to buy back shares from investors at a big premium.
AUSTIN, Texas, Jan. 14, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) announced today that it commenced a “modified Dutch auction” tender offer to purchase up to $420,00...
Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Antibody Program, Fuel Pipeline Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-...
XBiotech Move To Out-Licence Next Generation Antibody Brings In Substantial Cash For Pipeline Expansion
AUSTIN, Texas, Dec. 17, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The a...
XBiotech announced a massive deal with Johnson & Johnson subsidiary Janssen, which is thrusting the overlooked biopharma onto the radars of investors.
Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some.
XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen X...
Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Berme...
AUSTIN, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in a randomized, double-blind, placebo-controlled Phase 2 clinical study to evalu...
AUSTIN, Texas, Oct. 23, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 ...
Bermekimab Blocks Key Inflammatory Pathway in Systemic Sclerosis, a Devastating Disease with Currently No Approved Therapies Bermekimab Blocks Key Inflammatory Pathway in Systemic Sclerosis, a...
Results of the Company’s Phase 2 Trial to be Presented by Dr. Alice Gottlieb on Saturday, October 12, 2019 Results of the Company’s Phase 2 Trial to be Presented by Dr. Alice Gottlieb on Satur...
AUSTIN, Texas, Sept. 20, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) cove...
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
About XBIT
XBiotech, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. Its product candidates include 514G3, an anti-infective antibody that is in Phase II clinical trial for the treatment of Staphylococcus Aureus infections; and other anti-infectious disease antibodies, which are in pre-clinical development to treat Clostridium Diffici... [Read more...]
| Industry Biotechnology | IPO Date Apr 15, 2015 |
| CEO John Simard | Employees 89 |
| Stock Exchange NASDAQ | Ticker Symbol XBIT |
Analyst Forecasts
The average 12-month stock price forecast for XBiotech is 18.00, which is a decrease of -5.81% from the latest price.